Search

Your search keyword '"Ajroud-Driss, Senda"' showing total 209 results

Search Constraints

Start Over You searched for: Author "Ajroud-Driss, Senda" Remove constraint Author: "Ajroud-Driss, Senda"
209 results on '"Ajroud-Driss, Senda"'

Search Results

2. Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines

4. Multicenter expanded access program for access to investigational products for amyotrophic lateral sclerosis

5. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

6. Electrodiagnostic subtyping in Guillain–Barré syndrome patients in the International Guillain–Barré Outcome Study.

8. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial

9. Phrenic neuropathy etiologies and recovery trajectories in outpatient rehabilitation and neuromuscular medicine clinics: A retrospective analysis.

12. Plasma proteomic analysis on neuropathic pain in idiopathic peripheral neuropathy patients.

13. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

14. Evidence‐based consensus guidelines for ALS genetic testing and counseling.

15. The natural history of ALS: Baseline characteristics from a multicenter clinical cohort.

17. Primary lateral sclerosis natural history study – planning, designing, and early enrollment.

18. NaV channel variants in patients with painful and nonpainful peripheral neuropathy

20. Real-world Adherence to Nusinersen in Adults with Spinal Muscular Atrophy in the US: A Multi-site Chart Review Study

25. A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis

26. CIDP prognosis in patients with IVIG treatment‐related fluctuations.

27. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

28. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial

30. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy : 12-month results of an open-label extension study

32. A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis

35. Quantifying Treatment-Related Fluctuations in CIDP

36. ALS: Management Problems

40. ALS

41. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis

44. Impact of Patisiran on Overall Health Status in hATTR Amyloidosis : Results from the APOLLO Trial

45. Recent Advances in the Management of ALS: What Managed Care Needs to Know in an Evolving Treatment Paradigm.

46. New DEStiny Revealed: A Young Woman Post Ablation for WPW Syndrome with Recurrent Syncope and Progressive Myopathy

49. Impact of Patisiran on Overall Health Status in hATTR Amyloidosis: Results from the APOLLO Trial (S27.007)

Catalog

Books, media, physical & digital resources